Quarterly report pursuant to Section 13 or 15(d)

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)

3 Months Ended

Mar. 31, 2022

Schedule of the Computation of Basic and Diluted Net Loss Per Share of Common Stock

The following tables set forth the computation of basic and diluted net loss per share of common stock for the three months ended March 31, 2022, and common stock and preferred stock for the three months ended March 31, 2021 (in thousands, except share and per share amounts):


	Three Months Ended
	March 31, 2022
	Common stock
	Continuing Operations		Discontinued Operations
Numerator:
Allocation of undistributed net loss	$	(22,051)	$	—
Denominator:
Weighted average shares	112,794,203		112,794,203
Basic and diluted net loss per share	$	(0.20)	$	(0.00)


	Three Months Ended
	March 31, 2021
	Common stock				Preferred stock
	Continuing Operations		Discontinued Operations		Continuing Operations		Discontinued Operations
Numerator:
Allocation of undistributed net loss	$	(28,548)	$	(99)	$	(2,026)	$	(7)
Denominator:
Weighted average shares	88,576,559		88,576,559		1,257,143		1,257,143
Basic and diluted net loss per share	$	(0.32)	$	(0.00)	$	(1.61)	$	(0.01)

Schedule of Anti-dilutive Securities Excluded From Computation of Diluted Weighted Shares Outstanding

The following outstanding securities have been excluded from the computation of diluted weighted shares outstanding for the three months ended March 31, 2022 and 2021, as they could have been anti-dilutive:


	Three Months Ended
	March 31,
	2022	2021
Stock options	17,088,040	12,944,891
Warrants on common stock1	4,406,224	4,002,380
Restricted Stock Units	11,250	155,833

1 The weighted average number of common shares outstanding as of March 31, 2021 includes the weighted average effect of the 1,676,923 pre-funded warrants issued in connection with the underwritten public offering that closed in January 2021 because the exercise of such warrants requires only nominal consideration ($0.001 per share exercise price for each pre-funded warrant). During 2021, the holder exercised 308,880 of the pre-funded warrants. As of March 31, 2022, the weighted average number of common shares outstanding includes the weighted average effect of the remaining 1,368,043 pre-funded warrants outstanding. These pre-funded warrants are not included in the table above.